Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BMS Counting On Initial Combo Use For Glucovance To Supplant Glucophage

Executive Summary

Bristol-Myers Squibb's Glucovance (metformin/glyburide) is emerging from FDA in time to give Bristol a half a year or more to transfer the market from its $1.9 bil. single-agent product Glucophage to the new combo.

You may also be interested in...



Bristol Glucovance Has 1.5% Share; 60% Of Patients Are New To Metformin

Bristol-Myers Squibb's metformin/glyburide combination product Glucovance has a 1.5% share of the diabetes market one month after launch, Bristol told securities analysts Sept. 28 in New York City.

Bristol Glucovance Has 1.5% Share; 60% Of Patients Are New To Metformin

Bristol-Myers Squibb's metformin/glyburide combination product Glucovance has a 1.5% share of the diabetes market one month after launch, Bristol told securities analysts Sept. 28 in New York City.

Bristol Glucovance

Average wholesale price listed by First DataBank for metformin/glyburide combo (500 mg/2.5 mg) is $78.32 for 100 tablets, 11.8% above Bristol's Glucophage (metformin) 500 mg. The product was approved July 31 (1"The Pink Sheet" Aug. 7, p. 5)

Related Content

UsernamePublicRestriction

Register

PS036460

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel